
器官芯片、类器官和AI建模如何终结动物试验?
超过95%通过临床前动物试验的候选药物,最终在人体临床试验中失败。人类类器官、器官芯片与机器学习模型,如今提供了更为精准的数据驱动型预测工具。逐步淘汰默认使用的灵长类动物模型,将推动制药管线的现代化,并加速对未来大流行病的应对能力。
Juliana Hilliard is Co-Founder of Parallel Bio, where she's building human immune system organoids to replace animal testing in drug development. Before founding Parallel Bio in 2021, Juliana trained in the lab in Vienna, Austria that invented the first organoid. She developed foundational organoid technologies for the brain, which she then applied as an R&D lead for Herophilus (née System1 Biosciences). The organoid platform she helped build was used to discover novel neurological disease targets, and then was acquired by Genentech in 2023. Juliana holds an MSc in molecular bioengineering from the Technical University, Dresden, and a BS from Virginia Tech.
超过95%通过临床前动物试验的候选药物,最终在人体临床试验中失败。人类类器官、器官芯片与机器学习模型,如今提供了更为精准的数据驱动型预测工具。逐步淘汰默认使用的灵长类动物模型,将推动制药管线的现代化,并加速对未来大流行病的应对能力。
Primate testing is no longer the scientific gold standard. Here is why the pharmaceutical industry must commit to a human-first timeline by 2030.
